Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab After SBRT for Early Stage NSCLC
NCT03574220Phase 1Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Percent of patients tolerant to study drug up to 12 months. Planned start Feb 2019; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03574220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574220.